adenocarcinoma
transitional cell carcinoma
squamous cell carcinoma
basal cell carcinoma
B. transitional cell carcinoma
10%
20%
30%
40%
only in females
associated with chronic irritation, polypoid cystitis, and cystitis glandularis
no risk for squamous cell carcinoma
treated with estrogen, if symptomatic
infiltrative proximal penile urethral carcinomas
infiltrative distal penile urethral carcinomas
recurrent proximal penile urethral carcinoma after laser resection
T3/N2/M0 at bulbar urethra
2%
5%
70%
90%
RB
cyclin A
HRAS
CD-44
the standard treatment is transurethral resection
the prognosis for inverted papilloma is pathetic, with a recurrence rate of approximately 65%
the likelihood of synchronous urothelial carcinoma is 26%
has been shown to harbor p53 gene mutations
increase the irrigation fluid and pursue the procedure
abort the procedure and leave a urethral catheter
perform cystogram and manage accordingly
perform abdominal exploration and manage accordingly
tumor stage
tumor grade
lymphovascular invasion
lymph node spread
multifocality
high tumor grade and advanced stage
presence of CIS
all of the above
sensitivity to chemotherapy and age at presentation
anatomic location and extent of the tumor
histologic type of the tumor and sensitivity to radiotherapy
tumors stage and grade
obstructive LUTS are common presentations and occur in association with carcinoma in situ
might present as perineal abscesses and fistulae
could be asymptomatic
venereal diseases increase the risk of urethral cancers
40 - 55%
55 - 70%
70 - 85%
85 - 100%
never
unlikely
likely
always
well-differentiated tumor with broad-based invasive font
marked atypia distributed on wide areas of superficial urothelium
atypia is present
no atypia but marked degenerative epithelial changes
30%
40%
50%
60%
rarely diagnosed at autopsy
the peak incidence occurs between ages 70 and 80
they occur twice as frequently in men as in women
none of the above
radical cysto-prostatectomy
anterior pelvic exenteration
bilateral pelvic lymphadenectomy
creation of a urinary diversion
epirubicin
mitomycin c
BCG
none of the above
patients with carcinoma in situ
patients with completely resected solitary tumor
patients with preserved kidney and liver functions after 2 courses of BCG
patients with leiomyosarcoma
there will be no target tumor tissue to work on
post-op. hematuria interacts unfavorably with BCG composition
of the risk of systemic absorption and sepsis
of the high risk of BCG reflux to kidneys while bladder irrigation
nodular or sessile lesions usually invade muscle
papillary bladder tumors are typical of low stage and grade
carcinoma in situ appears as a flat, velvety patch
sarcomas commonly invade bladder base and ureteral orifices causing obstructions
adenocarcinoma
transitional cell carcinoma
squamous cell carcinoma
basal cell carcinoma
undergo cystectomy
try mitomycin c
take a second course of BCG
take a second course of BCG + quinolones
continue the procedure as perforations at this site do no harm
abort the procedure and leave a urethral catheter
convert tumor removal to open method and repair the defect
perform abdominal exploration and manage accordingly
single intravesical chemotherapy
TURBT
intravesical BCG vaccine
multiple bladder biopsies
obstructive uropathy
painless hematuria
pain radiating to the groin
locally advanced tumor
cisplatin
BCG
mitomycin C
5-fluorouracil
obesity
consuming artificial sweeteners
asbestosis
analgesic abuse
upper ureter
middle ureter
lower ureter
comparable
immediately before operation
immediately before incision and post-operative for 1 day
immediately before incision and post-operative for 15 days
immediately before incision and post-operative for 30 days